ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023 19:33 ET
|
ADC Therapeutics SA
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in...
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 16:30 ET
|
Marker Therapeutics
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023 07:00 ET
|
ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023 07:21 ET
|
ADC Therapeutics SA
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE:...
Global Multiple Myeloma Market Research Report 2023-2030: Top 10 Markets, Epidemiology, Marketed Products, Pipeline Drugs, Patient Journey, Competitive Landscape
June 12, 2023 07:08 ET
|
Research and Markets
Dublin, June 12, 2023 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis"...
Global Gastric Cancer Market Expected to Accumulate a Revenue of $10,737.00 Million by 2031, Growing at a Healthy CAGR of 17.9% [350-Pages] | Initiative by Research Dive
June 01, 2023 09:02 ET
|
Research Dive
New York, USA, June 01, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global gastric cancer market is anticipated to rise at a stable CAGR of 17.9%, thereby...
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano
May 30, 2023 06:12 ET
|
Tessa Therapeutics Ltd
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 12, 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...